To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/4 cls
Actelion Ltd. (SIX:ATLN) UBS Guillaume van Renterghem Price target Buy 18% CHF39.90
van Renterghem raised his target to CHF61 from CHF46 after macitentan met the primary endpoint in the Phase III SERAPHIN trial to treat pulmonary arterial hypertension

Read the full 656 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers